Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MYLK antisense RNA 1 (MYLK-AS1)
- Target
- MYLK-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other (non-coding transcript)
01
Overview
MYLK antisense RNA 1 (MYLK-AS1) is a long non-coding RNA transcribed antisense to the myosin light chain kinase (MYLK) gene. MYLK-AS1 has no protein-coding potential. It acts as an oncogenic regulator in several cancers, notably hepatocellular carcinoma and non-small cell lung cancer, where it promotes cell proliferation, migration, invasion, and drug resistance. Mechanistically, MYLK-AS1 modulates EGFR/HER2-ERK1/2 signaling and can regulate glutamine metabolism, contributing to cancer progression and poor patient outcomes. Its high expression is associated with tumor aggressiveness and can serve as a biomarker or potential therapeutic target in some cancer settings[3][4][5].
- Other names
- MYLK-AS2MYLK antisense RNA 2 (non-protein coding)MYLK antisense RNA 1 (non-protein coding)MYLK antisense RNA 2
02
Mechanism of action
Regulation of EGFR/HER2 signaling, affecting cell proliferation and invasion; Promotion of glutamine metabolism leading to TKI resistance; Upregulation of downstream targets by lncRNA-mediated transcriptional control.
03
Biological functions
Positive regulation of cell proliferationPromotion of cell migration and invasionRegulation of EGFR/HER2-ERK1/2 signaling pathwayModulation of glutamine metabolism and TKI resistance (in NSCLC)Interaction with microRNA pathways
04
Disease associations
Cancer (hepatocellular carcinoma, NSCLC)Cancer progression and metastasisDrug resistance (NSCLC tyrosine kinase inhibitor resistance)
05
Safety considerations
Not directly associated with specific safety concerns yet; however, targeting lncRNAs can present delivery and specificity challengesPotential off-target effects in RNA-based therapies
06
Interacting drugs
EGFR inhibitors (e.g., GW583340)
2 more in the full profile.
07
Biomarkers
MYLK-AS1 expression (high levels correlate with poor prognosis and aggressive tumors in HCC)MYLK-AS1 as a biomarker for TKI resistance in NSCLC
Beyond the preview
Go deeper on MYLK antisense RNA 1 (MYLK-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYLK antisense RNA 1 (MYLK-AS1).